This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Shire Pharmaceuticals Group PLC

Drug Names(s): pegaspargase, pegylated L-asparaginase

Description: ONCASPAR is a pegylated version of E. coli L-asparaginase and is an oncolytic agent used in combination chemotherapy. Leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase and are dependent on an exogenous source of asparagine for survival. Rapid depletion of asparagine which results from treatment with the enzyme L-asparaginase, kills the leukemic cells. Normal cells, however, are less affected by the rapid depletion due to their ability to synthesize asparagine. Pegylation, or the attachment of multiple long chain polyethylene glycol chains to the enzyme, reduces the enzymes clearance and provides for less frequent dosing.

Deal Structure: Sigma-Tau no longer reports sales as of Q1 2010.

Enzon had licensed rights to ONCASPAR for North America and most of the Asia/Pacificregion to Rhone Poulenc Rorer, now part of Sanofi-Aventis. In June 2002, Enzon licensed back those rights from Sanofi-Aventis.

In October 2005, Enzon and Sanofi-Aventisamended the agreement for ONCASPAR. The amendment became effective in January 2006 and includes asignificant reduction in Enzon's royalty rate, with a single-digit royalty percentage now payable by Enzon only on those aggregate annual sales of ONCASPAR in the U.S. and Canada that are in excess of $25.0 million. Previously, Enzon wasobligated to pay a 25% royalty on all sales of ONCASPAR in the U.S. and Canada.

Under the amended agreement, Enzon made an upfront cash payment of $35.0 million to Sanofi-Aventis in January 2006 and is obligated to make royalty payments through June 30, 2014, at which time all of its royalty obligations will cease.

In November 2009, Enzon...See full deal structure in Biomedtracker

Partners: Sanofi Enzon Pharmaceuticals, Inc.

Oncaspar News

Pink Sheet Enzon’s Oncaspar

Pink Sheet Enzon's Oncaspar

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug